SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44
Year: 2026
Type: article
Abstract: Non-small cell lung cancer (NSCLC) constitutes a significant proportion of lung cancers and poses a serious threat to human health. Osimertinib is the first-line drug for treating NSCLC, but long-term use can lead to drug resistance. Exploring the mechanism of drug resistance and effectively selecting treatment plans based on the mechanism of resistance are urgent issues to be addressed. In this study, dryness characteristics were evaluated by measuring cell activity, cell spheroid formation and cloning conditions, and the levels of stem cell marker molecules. The sensitivity of SPP1 to osimertinib was also assessed in mice. The results showed that SPP1 regulates cancer stem cells (CSCs) by interacting with CD44, thereby generating osimertinib resistance. These findings provide a basis for clinical research.
Source: Cancer Cell International
Authors: Hong Bi, Lewei He, Liyan Wang, Lijuan Yang, Jing Shao, Hang Li, Xiang Guo, Hong Liu, Yaping Fu, Huiming Wang, Yue Wang, Zhixian Jin, Min Chen
Institutions: Kunming Medical University, The First Hospital of Kunming
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
Award: G4964541672
OpenAlex ID: W7123555701